JP2012505901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505901A5 JP2012505901A5 JP2011532205A JP2011532205A JP2012505901A5 JP 2012505901 A5 JP2012505901 A5 JP 2012505901A5 JP 2011532205 A JP2011532205 A JP 2011532205A JP 2011532205 A JP2011532205 A JP 2011532205A JP 2012505901 A5 JP2012505901 A5 JP 2012505901A5
- Authority
- JP
- Japan
- Prior art keywords
- wsp
- fviii
- antibody
- item
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10554808P | 2008-10-15 | 2008-10-15 | |
| US61/105,548 | 2008-10-15 | ||
| PCT/US2009/060633 WO2010045321A2 (en) | 2008-10-15 | 2009-10-14 | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505901A JP2012505901A (ja) | 2012-03-08 |
| JP2012505901A5 true JP2012505901A5 (enExample) | 2012-04-19 |
| JP4966434B2 JP4966434B2 (ja) | 2012-07-04 |
Family
ID=42035746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532205A Expired - Fee Related JP4966434B2 (ja) | 2008-10-15 | 2009-10-14 | 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8143347B2 (enExample) |
| EP (1) | EP2349341B1 (enExample) |
| JP (1) | JP4966434B2 (enExample) |
| AU (1) | AU2009303368B2 (enExample) |
| CA (1) | CA2738064C (enExample) |
| DK (1) | DK2349341T3 (enExample) |
| ES (1) | ES2441941T3 (enExample) |
| PL (1) | PL2349341T3 (enExample) |
| WO (1) | WO2010045321A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| GB201910190D0 (en) * | 2012-04-16 | 2019-08-28 | Cantab Biopharmaceuticals Patents Ltd | Optimised subsutaneous therapeutic agents |
| CN102776260B (zh) * | 2012-07-26 | 2015-04-29 | 上海泰龙生物医药科技有限公司 | 一种高效表达重组人凝血八因子的方法 |
| KR20150133576A (ko) | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
| CN105237762B (zh) * | 2015-10-27 | 2017-11-14 | 深圳市健元医药科技有限公司 | Peg化亮丙瑞林 |
| KR20190112747A (ko) | 2017-02-01 | 2019-10-07 | 노보 노르디스크 에이/에스 | 응고촉진 항체 |
| WO2019222674A1 (en) * | 2018-05-18 | 2019-11-21 | Chan Zuckerberg Biohub, Inc. | Epitope restriction for antibody selection |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| CN111378026A (zh) * | 2018-12-27 | 2020-07-07 | 天津键凯科技有限公司 | 一种制备结合位点可控的peg化生物分子的方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686112A (en) * | 1983-01-13 | 1987-08-11 | Rca Corporation | Deposition of silicon dioxide |
| US4757006A (en) * | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| AU5772886A (en) | 1985-04-12 | 1986-11-05 | Genetics Institute Inc. | Novel procoagulant proteins |
| US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5250421A (en) * | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU8507191A (en) * | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| WO1994007510A1 (en) * | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| WO1999003496A1 (en) * | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| US7074878B1 (en) * | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| MXPA04004336A (es) * | 2001-11-07 | 2005-05-16 | Nektar Therapeutics Al Corp | Polimeros ramificados y sus conjugados. |
| WO2004075923A2 (en) * | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| RU2333223C2 (ru) * | 2003-08-12 | 2008-09-10 | Лайпоксен Текнолоджиз Лимитед | Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе |
| WO2006016168A2 (en) * | 2004-08-12 | 2006-02-16 | Lipoxen Technologies Limited | Sialic acid derivatives |
| PT2279758E (pt) | 2005-06-16 | 2015-05-27 | Nektar Therapeutics | Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados |
| KR20080108147A (ko) * | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
-
2009
- 2009-10-14 AU AU2009303368A patent/AU2009303368B2/en not_active Ceased
- 2009-10-14 ES ES09748174.1T patent/ES2441941T3/es active Active
- 2009-10-14 US US12/578,948 patent/US8143347B2/en active Active
- 2009-10-14 EP EP09748174.1A patent/EP2349341B1/en active Active
- 2009-10-14 DK DK09748174.1T patent/DK2349341T3/da active
- 2009-10-14 PL PL09748174T patent/PL2349341T3/pl unknown
- 2009-10-14 CA CA2738064A patent/CA2738064C/en active Active
- 2009-10-14 WO PCT/US2009/060633 patent/WO2010045321A2/en not_active Ceased
- 2009-10-14 JP JP2011532205A patent/JP4966434B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500343A5 (enExample) | ||
| Biran et al. | Heparin coatings for improving blood compatibility of medical devices | |
| Li et al. | Lysine-PEG-modified polyurethane as a fibrinolytic surface: effect of PEG chain length on protein interactions, platelet interactions and clot lysis | |
| JP2018035192A5 (enExample) | ||
| EP2718724B1 (en) | Diagnostic devices, methods and systems for detecting platelet factor 4 (pf4)/heparin antibodies | |
| US6884628B2 (en) | Multifunctional polymeric surface coatings in analytic and sensor devices | |
| Ahmed et al. | Hyperbranched glycopolymers for blood biocompatibility | |
| Nguyen et al. | Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds | |
| Yu et al. | Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry | |
| JP2015506764A (ja) | 止血創傷被覆材 | |
| AR084576A1 (es) | Materiales y metodos para conjugar un derivado de acido graso hidrosoluble a una proteina | |
| CA2744340A1 (en) | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay | |
| US12208132B2 (en) | Therapeutic APAC molecule comprising heparin conjugated to a plasma protein | |
| RU2016121611A (ru) | Конъюгаты белков свертывания крови | |
| Hakim | Complement activation by biomaterials | |
| La et al. | Targeting biological polyanions in blood: strategies toward the design of therapeutics | |
| JP4966434B2 (ja) | 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化 | |
| JP7676032B2 (ja) | Ｐｅｇ－脂質 | |
| Cheng et al. | Simultaneous Removal of Endotoxin and Circulating Histones by Heparin-Grafted Chitosan-Cellulose Composite Microspheres for Multitargeted Hemoperfusion in Septic Blood | |
| Yavari et al. | Anticoagulant therapy during cardiopulmonary bypass | |
| Jung et al. | QCM and AFM analysis of anticoagulant activities of sulfonated polymers against fibrin formation | |
| Simberg et al. | Complement activation by nanomaterials | |
| JP2013135704A (ja) | 止血材及びその製造方法 | |
| JP2004510162A5 (enExample) | ||
| Simak | The effects of engineered nanomaterials on the plasma coagulation system |